ACURA PHARMACEUTICALS Enters Material Agreement, Completes Acquisition
| Field | Detail |
|---|---|
| Company | Acura Pharmaceuticals, Inc |
| Form Type | 8-K |
| Filed Date | Apr 23, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, acquisition, financial-obligation
TL;DR
ACURA PHARMACEUTICALS just signed a big deal and closed an asset acquisition. Big moves happening!
AI Summary
On April 18, 2025, ACURA PHARMACEUTICALS, INC. entered into a material definitive agreement and completed the acquisition or disposition of assets. The company also incurred a direct financial obligation or an obligation under an off-balance sheet arrangement. Specific details regarding the agreement, acquisition, and financial obligations are not provided in this filing.
Why It Matters
This filing indicates significant corporate actions by ACURA PHARMACEUTICALS, INC., including a new agreement and asset transaction, which could impact its business operations and financial standing.
Risk Assessment
Risk Level: medium — The filing indicates material definitive agreements and asset transactions, which inherently carry business and financial risks.
Key Players & Entities
- ACURA PHARMACEUTICALS, INC. (company) — Registrant
- April 18, 2025 (date) — Date of earliest event reported
- 110853640 (company) — EIN
- NY (state) — State of incorporation
- 1-10113 (company) — SEC File Number
FAQ
What type of material definitive agreement did ACURA PHARMACEUTICALS, INC. enter into?
The filing states that ACURA PHARMACEUTICALS, INC. entered into a material definitive agreement, but the specific details of the agreement are not disclosed in this Form 8-K.
What assets were acquired or disposed of by ACURA PHARMACEUTICALS, INC.?
The filing indicates the completion of an acquisition or disposition of assets by ACURA PHARMACEUTICALS, INC., but does not specify the nature or value of these assets.
What is the nature of the direct financial obligation or off-balance sheet arrangement incurred by ACURA PHARMACEUTICALS, INC.?
ACURA PHARMACEUTICALS, INC. reported the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement, but the specifics are not detailed in this report.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing by ACURA PHARMACEUTICALS, INC. occurred on April 18, 2025.
What is ACURA PHARMACEUTICALS, INC.'s former company name and when was the name change?
ACURA PHARMACEUTICALS, INC.'s former company name was HALSEY DRUG CO INC/NEW, and the date of the name change was July 3, 1992.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 23, 2025 regarding ACURA PHARMACEUTICALS, INC.